Curated News
By: NewsRamp Editorial Staff
December 22, 2025
NeuroOne Appoints Med-Tech Veteran Jason Mills to Board
TLDR
- NeuroOne appoints Jason Mills to its Board, gaining strategic med-tech expertise and industry relationships to advance clinical goals and create shareholder value.
- Jason Mills brings over two decades of med-tech investment analysis and executive strategy experience from Penumbra to NeuroOne's Board, effective December 18, 2025.
- This appointment strengthens NeuroOne's mission to transform neurological disorder treatments, potentially improving patient outcomes for conditions like epilepsy and Parkinson's disease.
- A former top-ranked Wall Street medical devices analyst joins NeuroOne's Board, bringing Yale economics and sports administration credentials to neurological innovation.
Impact - Why it Matters
This board appointment signals NeuroOne's strategic focus on accelerating growth and leveraging deep industry expertise. For patients suffering from debilitating neurological disorders like epilepsy and Parkinson's disease, it represents a potential acceleration in the development of less invasive, more effective treatments. For investors, it brings a seasoned analyst with a proven track record of identifying value in med-tech companies into a key governance role, potentially enhancing strategic decision-making and market positioning. In the broader healthcare landscape, moves like this often precede significant advancements in medical technology, as experienced leaders help bridge the gap between innovative R&D, clinical application, and sustainable commercialization, ultimately aiming to bring new hope and improved care standards to patients worldwide.
Summary
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC), a medical technology company dedicated to transforming the surgical diagnosis and treatment of neurological disorders, has announced a significant addition to its leadership team. The company appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills brings a formidable combination of corporate strategy and financial analysis experience to NeuroOne, currently serving as Executive Vice President of Strategy at NYSE-listed Penumbra, Inc., the world's leading thrombectomy company. His background includes over two decades as a dedicated med-tech investment analyst, most notably as Managing Director and head of the medical technology equity research practice at Canaccord Genuity for over 13 years, where he earned prestigious awards for his equity research.
NeuroOne's leadership expressed strong enthusiasm for the appointment. CEO Dave Rosa highlighted Mills's "unparalleled and invaluable experience and insights in med-tech," noting his firsthand industry knowledge and capital markets expertise will be a critical resource as the company progresses on its clinical and corporate goals. Board Chairman Paul Buckman added that Mills will help expand the company's reach as it works to transform neurological disorder treatment and create additional value for shareholders. Mills will also serve on the Compensation and Nominating & Corporate Governance Committees, further integrating his strategic vision into the company's governance.
This strategic board appointment comes as NeuroOne continues to develop and commercialize its portfolio of minimally invasive, hi-definition solutions. The company's technologies target a range of challenging neurological conditions, including epilepsy, Parkinson's disease, dystonia, essential tremors, and chronic pain. Their innovative approaches to EEG recording, monitoring, ablation, drug delivery, and stimulation aim to improve patient outcomes while reducing procedural costs. The original release can be viewed on www.newmediawire.com, and for more information about NeuroOne's pioneering work, visit nmtc1.com.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, NeuroOne Appoints Med-Tech Veteran Jason Mills to Board
